Results 241 to 250 of about 100,602 (348)
Morphological analysis of the early stages of oligodendrocyte development in the vertebrate central nervous system [PDF]
Robert H. Miller, Katsuhiko Ono
openalex +1 more source
Abstract Background The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP). Objective To investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP.
Hui Wang+93 more
wiley +1 more source
Exosomes increase mitochondrial transcription factor A (TFAM) expression in DPSCs by transferring TFAM mRNA. Moreover, highly expressed TFAM in DPSCs enhances GDH expression and OXPHOS activity. Meanwhile, glutamate metabolism provides amounts of NADH to OXPHOS.
Jia Guo+9 more
wiley +1 more source
Intrinsic retinoic acid synthesis is required for oligodendrocyte progenitor expansion during CNS remyelination. [PDF]
Nanescu SE+11 more
europepmc +1 more source
Molecular heterogeneity of oligodendrocytes in chicken white matter [PDF]
Emma S. Anderson+3 more
openalex +1 more source
Preventive Effect of Upland Pigmented Potatoes Against LPS‐Induced Inflammation in THP‐1 Macrophages
The anti‐inflammatory activity of extracts from three commercial potato varieties cultivated upland was investigated on THP‐1 macrophages insulted with LPS. While the chlorogenic acid (CGA)‐rich extract from Kennebec reduced inflammation only at supraphysiological doses, carotenoid‐rich Desirèe and anthocyanin (ACN)‐rich Bleuet decreased TNF‐α, IL‐1β ...
Marta Toccaceli+10 more
wiley +1 more source
CoTF-reg reveals cooperative transcription factors in oligodendrocyte gene regulation using single-cell multi-omics. [PDF]
Choi JJ, Svaren J, Wang D.
europepmc +1 more source
TPO1, a Member of a Novel Protein Family, Is Developmentally Regulated in Cultured Oligodendrocytes [PDF]
Winfried Krueger+6 more
openalex +1 more source
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
ABSTRACT Introduction/Aims Tofersen is approved for the treatment of amyotrophic lateral sclerosis (ALS) due to superoxide dismutase 1 mutations (SOD1‐ALS). Here we report serious neurologic adverse events (AEs) that occurred in the tofersen clinical trials in people with SOD1‐ALS.
Alexandra Lovett+17 more
wiley +1 more source